OBJECTIVE: To examine how a healthy lifestyle is related to life expectancy that is free from major chronic diseases.DESIGN: Prospective cohort study.SETTING AND PARTICIPANTS: The Nurses' Health Study (1980-2014; n=73 196) and the Health Professionals Follow-Up Study (1986-2014; n=38 366).MAIN EXPOSURES: Five low risk lifestyle factors: never smoking, body mass index 18.5-24.9, moderate to vigorous physical activity (≥30 minutes/day), moderate alcohol intake (women: 5-15 g/day; men 5-30 g/day), and a higher diet quality score (upper 40%).MAIN OUTCOME: Life expectancy free of diabetes, cardiovascular diseases, and cancer.RESULTS: The life expectancy free of diabetes, cardiovascular diseases, and cancer at age 50 was 23.7 years (95% confidence interval 22.6 to 24.7) for women who adopted no low risk lifestyle factors, in contrast to 34.4 years (33.1 to 35.5) for women who adopted four or five low risk factors. At age 50, the life expectancy free of any of these chronic diseases was 23.5 (22.3 to 24.7) years among men who adopted no low risk lifestyle factors and 31.1 (29.5 to 32.5) years in men who adopted four or five low risk lifestyle factors. For current male smokers who smoked heavily (≥15 cigarettes/day) or obese men and women (body mass index ≥30), their disease-free life expectancies accounted for the lowest proportion (≤75%) of total life expectancy at age 50.CONCLUSION: Adherence to a healthy lifestyle at mid-life is associated with a longer life expectancy free of major chronic diseases.
Recently, a role for uncoupling protein-3 (UCP3) in carbohydrate metabolism and in type 2 diabetes has been suggested. Mice overexpressing UCP3 in skeletal muscle showed reduced fasting plasma glucose levels, improved glucose tolerance after an oral glucose load, and reduced fasting plasma insulin levels. However, data regarding the expression of UCP3 in patients with type 2 diabetes is inconsistent, and so far, there have been no reports of UCP3 protein content. Here we compared, for the first time, the protein levels of UCP3 in vastus lateralis muscle in 14 male type 2 diabetic patients (age 49.8 +/- 2.1 years; BMI 27.2 +/- 1.2 kg/m(2); mean +/- SE) with 16 male control subjects (age 48.0 +/- 1.9 years; BMI 23.4 +/- 0.6 kg/m(2)). We found that UCP3 protein levels were twice as low in patients with type 2 diabetes compared with control subjects (117 +/- 16 vs. 58 +/- 12 AU; P = 0.007). There was no correlation between UCP3 content and BMI. In conclusion, UCP3 content is lower in type 2 diabetic patients compared with healthy control subjects. These results are consistent with a role for UCP3 in glucose homeostasis and suggest a role for UCP3 in type 2 diabetes.
Background: Weight loss is key to treatment of older adults with obesity and type 2 diabetes, but also a risk for muscle mass loss. This study investigated whether a whey protein drink enriched with leucine and vitamin D could preserve muscle mass and improve glycemic control during combined lifestyle intervention in this population. Methods: 123 older adults with obesity and type 2 diabetes were randomized into a 13-week lifestyle intervention with dietary advice and exercise, receiving either the enriched protein drink (test) or an isocaloric control (control). Muscle mass was assessed with dual-energy X-ray absorptiometry and glycemic control by oral glucose tolerance test. Statistical analyses were performed using a linear mixed model. Results: There was a nonsignificant increase in leg muscle mass (+0.28 kg; 95% CI, −0.01 to 0.56) and a significant increase in appendicular muscle mass (+0.36 kg; 95% CI, 0.005 to 0.71) and total lean mass (+0.92 kg; 95% CI, 0.19 to 1.65) in test vs. control. Insulin sensitivity (Matsuda index) also increased in test vs. control (+0.52; 95% CI, 0.07 to 0.97). Conclusions: Use of an enriched protein drink during combined lifestyle intervention shows beneficial effects on muscle mass and glycemic control in older adults with obesity and type 2 diabetes.
Mensen met een lage sociaaleconomische status (SES) hebben relatief vaak te maken met diabetes type 2. Patiënten bij wie deze diagnose gesteld wordt, krijgen van hun huisarts en/of diens praktijkondersteuner het advies om gezonder te leven. Huisartsen en praktijkondersteuners merken echter dat ze patiënten met een lage SES onvoldoende effectief bereiken met hun leefstijladvies. Ook andere professionals vinden het moeilijk om mensen met een lage SES daadwerkelijk te bereiken. Hoewel bedrijven in de creatieve industrie zeer goed in staat zijn oplossingen te ontwerpen met en voor specifieke doelgroepen, merken zij dat het lastig is lage SES groepen actief te betrekken in het ontwerpproces. In deze KIEM aanvraag gaan creatieve industrie, praktijkgerichte onderzoekers en het Expertisecentrum Gezondheidsverschillen de samenwerking aan in ontwerponderzoek bij patiënten met een lage SES. Het project levert daarmee unieke ervaringen en kennis op over ontwerpen met en voor mensen met een lage SES en hun gezondheidsproblematiek. Ook geeft het project inzicht in hoe type-2-diabetespatiënten met een lage SES aankijken tegen een gezond leven en worden er aanknopingspunten geïdentificeerd voor het ontwerpen van strategieën ter bevordering van een gezond leven met diabetes. Het project draagt daarmee bij aan het oplossen van een belangrijk maatschappelijk probleem: gezondheidsverschillen. Deze aanvraag dient nadrukkelijk als opmaat naar samenwerking in een groter project.
12.000 kinderen in Nederland hebben de chronische ziekte Diabetes Type 1. Vanaf het moment van diagnose is het leven alles behalve zorgeloos. Een manier, die voorbereid op het leven met Diabetes en de met emoties beladen situaties waarin gehandeld moet worden, is er niet. Uit een korte, niet wetenschappelijke, enquête (n = 68) blijkt dat er vraag is naar een app die leert omgaan met de ziekte. Onze oplossing hiervoor is een integrale app met een serious game en verschillende functionaliteiten. Doormiddel van een haalbaarheidsonderzoek willen wij de behoeftes van deze doelgroep nog beter in kaart brengen en mogelijk vervullen.
Over a million people in the Netherlands have type 2 diabetes (T2D), which is strongly related to overweight, and many more people are at-risk. A carbohydrate-rich diet and insufficient physical activity play a crucial role in these developments. It is essential to prevent T2D, because this condition is associated with a reduced quality of life, high healthcare costs and premature death due to cardiovascular diseases. The hormone insulin plays a major role in this. This hormone lowers the blood glucose concentration through uptake in body cells. If an excess of glucose is constantly offered, initially the body maintains blood glucose concentration within normal range by releasing higher concentrations of insulin into the blood, a condition that is described as “prediabetes”. In a process of several years, this compensating mechanism will eventually fail: the blood glucose concentration increases resulting in T2D. In the current healthcare practice, T2D is actually diagnosed by recognizing only elevated blood glucose concentrations, being insufficient for identification of people who have prediabetes and are at-risk to develop T2D. Although the increased insulin concentrations at normal glucose concentrations offer an opportunity for early identification/screening of people with prediabetes, there is a lack of effective and reliable methods/devices to adequately measure insulin concentrations. An integrated approach has been chosen for identification of people at-risk by using a prediabetes screening method based on insulin detection. Users and other stakeholders will be involved in the development and implementation process from the start of the project. A portable and easy-to-use demonstrator will be realised, based on rapid lateral flow tests (LFTs), which is able to measure insulin in clinically relevant samples (serum/blood) quickly and reliably. Furthermore, in collaboration with healthcare professionals, we will investigate how this screening method can be implemented in practice to contribute to a healthier lifestyle and prevent T2D.
